If they care to reflect, medtechs will remember 2022 and the lead into 2023 as one of the most challenging periods the industry has seen in decades.
MTI 100: Macro Challenges Make Demands Of Newly Resilient Medtechs
Healthcare transition accelerates while sustainability compliance demands attention
Global medtechs had a big enough challenge with COVID-19 and its aftermath before the full-scale regional conflict in Ukraine added more uncertainty to the question of when market normality would return.
More from Company Rankings
• By
Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.
The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.
• By
Top 100 publicly listed medtech companies ranked by global revenues, and listings for the top cardiology, orthopedic, IVD and imaging performers based on 2023 or 2023-24 revenues, are now available from Medtech Insight.
More from Market Intelligence
• By
Implementing a reflex test alongside traditional prostate cancer screening is cost-effective for high-risk groups, claims Prostate Cancer Research. Oxford BioDynamics sheds light on UK market conditions influencing the adoption of its reflex test, EpiSwitch PSE.
• By
Several counties in the US state of Georgia are maternity care “deserts.” Remote monitoring of high-risk pregnancies with maternal hypertension and diabetes could help improve the state’s high rate of maternal mortality, according to leading health service provider Philips.
• By
Medtronic’s US FDA approval for BrainSense aDBS and BrainSense EI software features of the Percept neurostimulator device has quickly followed CE marking in January.